Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2020-03-16 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, compliance with relevant laws and regulations, and the company's plans to continue the repurchase within the authorized limits. The document does not contain financial statements or detailed financial analysis but focuses on the company's transactions in its own shares. This matches the definition of a 'Transaction in Own Shares' filing, which reports on share buybacks or sales by the company itself.
2020-03-16 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, prices, compliance with regulations, and the company's plans to continue the buyback. The document is titled as a progress announcement and does not contain full financial statements or comprehensive financial analysis. It fits the category of a report on the company's transactions in its own shares (share repurchase). Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length is 1675 characters, which is consistent with an announcement rather than a full report.
2020-03-02 Chinese
关于获得盐酸莫西沙星片药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration approval from the National Medical Products Administration (国家药品监督管理局). It provides details about the drug, its registration, and its potential market impact. The document is short (1040 characters) and serves as a formal announcement of regulatory approval rather than a financial report or detailed corporate filing. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best as a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-02-28 Chinese
2019年度业绩快报
Earnings Release Classification · 95% confidence The document is titled as a 2019 annual performance bulletin (业绩快报) from Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains preliminary financial data for the full year 2019, including revenue, profit, net profit attributable to shareholders, earnings per share, and return on equity. The data is noted as preliminary and internally audited but not yet audited by an external accounting firm, with a caution about possible differences from the final annual report. The document also includes explanations of business performance, R&D activities, and comparison with previous forecasts. The length is about 2150 characters, which is relatively short and typical for a performance bulletin or earnings release rather than a full annual report. It is not a full 10-K or Annual Report because it lacks comprehensive financial statements and detailed disclosures. It is not a Regulatory Filing or Report Publication Announcement because it contains substantive financial data and analysis, not just a notice. The document is best classified as an Earnings Release (ER) because it provides initial key financial results for the year 2019 with some narrative explanation, but it is preliminary and not the full annual report. FY 2019
2020-02-28 Chinese
关于JK07获得美国FDA药品临床试验批准的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval by the US FDA for clinical trials of a new drug JK07. It contains no financial statements or detailed financial data, but rather regulatory and clinical trial approval information. The document is short (1635 characters) and serves as a formal disclosure of a regulatory event related to drug development. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it does not mention any report being published or attached. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about FDA approval for clinical trials, which does not fit other more specific categories.
2020-02-24 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, prices, compliance with relevant laws and regulations, and the company's plans to continue the repurchase within the authorized limits. The document does not contain financial statements or comprehensive financial data but focuses on the update of the company's share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buying back or selling its own shares.
2020-02-04 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.